Stirring around Biontech and Curevac – biotech firms in Tübingen aren’t running out of steam
stuttgarter-nachrichten.de/inhalt.wirbel-um-biontech-und-curevac-biofirmen-in-tuebingen-geht-die-puste-nicht-aus.b1a93e4e-f1d7-4665-a276-748a405b7a92.html
Photo: stuttgarter-nachrichten.de · view article
Tübingen’s Biotech Sector Adapts Beyond CurevacIn 2026, Cegat, Intavis, and HB Technologies expect revenue growth while Curevac staff find new employment opportunities locally.
Key FactsMay 11, 2026 · Reading time: ~45 sec.
Summary created with AI assistance · Source: stuttgarter-nachrichten.de
Summary created with AI assistance · Source: stuttgarter-nachrichten.de
- Cegat anticipates increased revenues in 2026 and considers expanding its site, currently employing 220 people.
- Intavis projects significant sales growth and may build a new technology facility on available land.
- Immatics employs about 300 staff in Tübingen and is funded through venture capital and partnerships without market revenues.
- Several companies like Cegat, HB Technologies, and Immatics seek skilled professionals, including former Curevac employees.
But you can't absorb 780 employees all at once in Tübingen.— Thorsten Flink, managing director of the city's economic development company, on the potential transfer of Curevac employees.
Story Details
| Last Updated | |
| Total Articles | 1 |
Main Topics
yearly report on a company or other organization's activities; publication type
part of a corporate structure that deals with strategic planning, corporate communications, taxes, law, marketing, finance, human resources, and information technology etc
Similar to This
Previous
Multi-million euro offer for plant in Tübingen: 500 CureVac employees to be taken on
swp.de/lokales/tuebingen/millionenangebot-fuer-werk-in-tuebingen-500-mitarbeiter-von-curevac-sollten-uebernommen-werden-79573804.html
Film about Ingmar Hoerr and CureVac in Tübingen: Saving the world in a flash: A biopic about mRNA pioneer and CureVac founder Ingmar Hoerr premieres at the Hof ...
swp.de/lokales/tuebingen/kultur-tuebingen/film-ueber-curevac-in-tuebingen-mal-eben-kurz-die-welt-retten-79556685.html
Paid articlePaywall OpinionMillion-dollar bonuses: Boris Palmer rants: Payments to CureVac manager "outrageous"
stuttgarter-nachrichten.de/wirtschaft/millionen-boni-boris-palmer-empoerend-hohe-zahlungen-an-curevac-manager-79539819.html
OpinionAfter CureVac's exit in Tübingen: What is the state government's CureVac task force actually doing?
swp.de/lokales/tuebingen/nach-curevac-aus-in-tuebingen-was-macht-eigentlich-die-curevac-taskforce-der-landesregierung-79521574.html
Paid articlePaywall
"That's impossible": BioNTech breaks promises - | 1,800 people lose their jobs in Germany
op-online.de/wirtschaft/biontech-schliesst-drei-standorte-1800-jobs-weg-kein-kaeufer-gefunden-zr-94518629.html
CureVac in Tübingen: Takeover by BioNTech and sites in danger: BioNTech acquired CureVac for $1.25 billion at the end of last year and will now close all CureVac ...
sueddeutsche.de/wirtschaft/ugur-sahin-oezlem-tuereci-ingmar-hoerr-struengmann-mrna-impfstoffe-mrna-krebs-moderna-li.3522088
Paid articlePaywallWill the Tübingen site be completely closed?: Clarity on BioNTech locations by the end of September
swp.de/lokales/tuebingen/tuebinger-standort-bedroht-klarheit-ueber-biontech-standorte-bis-ende-september-79418978.html
CureVac and BioNTech in Tübingen: These were the promises for the CureVac location in Tübingen back in 2025
swp.de/lokales/tuebingen/curevac-und-biontech-in-tuebingen-das-waren-noch-2025-die-versprechungen-fuer-den-curevac-standort-tuebingen-79108233.html
Paid articlePaywall BioNTech closes CureVac site in Tübingen: What happened to 300 million euros of taxpayers' money
op-online.de/wirtschaft/curevac-und-biontech-wie-der-impfstoff-traum-der-merkel-aera-endet-zr-94355314.html
BioNTech plans to close plant with 750 employees - | despite share deal with government
businessinsider.de/wirtschaft/biontech-will-werk-mit-750-mitarbeitern-schliessen-trotz-aktien-deal-mit-regierung/
Paid articlePaywallAfter CureVac's exit from Tübingen: Mayor Palmer and BioNTech are exploring solutions to preserve the site
swp.de/lokales/tuebingen/nach-curevac-aus-in-tuebingen-ob-palmer-und-biontech-pruefen-loesungen-fuer-erhalt-des-standorts-79076630.html
Biotech Earthquake in Tübingen: "Soulless, brazen, total catastrophe" - | CureVac Specialist Offers Insights
swp.de/lokales/tuebingen/biotech-beben-in-tuebingen-seelenlos-dreist-totale-katastrophe-curevac-spezialist-im-interview-79063934.html
Paid articlePaywall
Pharmaceutical industry: CureVac founder accuses BioNTech of deception: Shortly after the acquisition, BioNTech announced the closure of CureVac's former ...
zeit.de/wirtschaft/unternehmen/2026-05/curevec-gruender-vorwurf-taeuschung-biontech
Biotech: BioNTech finalizes CureVac acquisition: The merger of the two vaccine developers is complete. BioNTech is acquiring its competitor CureVac - | and thus ...
handelsblatt.com/unternehmen/industrie/biotech-biontech-macht-uebernahme-von-curevac-perfekt/100185010.html
Share swap - | Biontech launches offer to Curevac shareholders: The deadline for the share swap is December 3rd. The former competitors plan to conduct joint ...
stuttgarter-nachrichten.de/inhalt.aktientausch-biontech-startet-angebot-an-curevac-aktionaere.9753c233-bf64-4877-8fed-36fe7b77f02d.html
Antitrust authority approves BioNTech's acquisition of CureVac: Why do competition watchdogs see no threat to innovation in the merger between BioNTech and ...
giessener-allgemeine.de/wirtschaft/kartellamt-erlaubt-kauf-von-curevac-durch-biontech-zr-93985421.html
Curevac and Biontech end dispute: Agreement thanks to takeover: Curevac and its partner GSK will receive a total of 740 million euros for the rights to Covid-19 ...
swp.de/lokales/tuebingen/curevac-und-biontech-beenden-streit-einigung-dank-uebernahme-78234691.html
Paid articlePaywall Pharma industry: Biontech halves loss - cancer strategy picks up speed: Biontech more than doubled its turnover in the second quarter. The company plans to spend ...
handelsblatt.com/unternehmen/industrie/pharmaindustrie-biontech-halbiert-verlust-krebsstrategie-nimmt-fahrt-auf/100146054.html
Key FactsBiontech Boosts Growth with Cancer Strategy and Deals
Aug 4, 2025 · Reading time: ~45 sec.
Summary created with AI assistance · Source: handelsblatt.com
Summary created with AI assistance · Source: handelsblatt.com
- Biontech doubled its revenue to €260.8 million in Q2 and reduced its net loss to €386.6 million.
- The company is refocusing on oncology, strengthened by a partnership with Bristol Myers Squibb and the planned acquisition of Curevac.
- Over 20 studies involving BNT327 across various tumors are underway, with a pivotal breast cancer phase-3 study starting this year.
- Revenue is forecasted to decline in 2025 while R&D spending is expected to increase to as much as €2.8 billion.
We continue to invest significantly in the implementation of our strategy, and our operational and financial measures are showing initial tangible results.— CFO Ramón Zapata discusses Biontech's progress in cancer research.
Next